1. Home
  2. ENB vs VRTX Comparison

ENB vs VRTX Comparison

Compare ENB & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enbridge Inc

ENB

Enbridge Inc

HOLD

Current Price

$54.47

Market Cap

118.5B

Sector

Energy

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$434.02

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENB
VRTX
Founded
1949
1989
Country
Canada
United States
Employees
14800
N/A
Industry
Natural Gas Distribution
EDP Services
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
118.5B
115.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
ENB
VRTX
Price
$54.47
$434.02
Analyst Decision
Strong Buy
Buy
Analyst Count
2
29
Target Price
$65.00
$539.08
AVG Volume (30 Days)
4.0M
1.2M
Earning Date
05-08-2026
05-04-2026
Dividend Yield
5.03%
N/A
EPS Growth
N/A
836.54
EPS
N/A
15.32
Revenue
N/A
$2,488,652,000.00
Revenue This Year
N/A
$10.81
Revenue Next Year
$3.92
$10.26
P/E Ratio
$21.67
$29.64
Revenue Growth
N/A
46.20
52 Week Low
$39.73
$362.50
52 Week High
$55.11
$510.77

Technical Indicators

Market Signals
Indicator
ENB
VRTX
Relative Strength Index (RSI) 60.79 35.99
Support Level $46.65 $403.16
Resistance Level N/A $465.98
Average True Range (ATR) 0.83 12.12
MACD -0.10 -3.61
Stochastic Oscillator 73.56 2.03

Price Performance

Historical Comparison
ENB
VRTX

About ENB Enbridge Inc

Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: